International Journal of Clinical Research

Objective: To explore the influencing factors of reocclusion and the effect of alteplase intravenous thrombolysis in the treatment of cerebral infarction patients. Methods: 100 patients with cerebral infarction admitted to our hospital from May 2023 to May 2024 were selected to group for cerebral infarction with alteplase intravenous thrombolysis. The occlusion was included in the control group, and 50 cases were included in each group. The observation group was given tirofiban treatment. Analysis of the factors of re-occlusion with alteplase intravenous thrombolytic therapy in patients with cerebral infarction in combination with Logistic regression model. Values of the recombinant human tissue plasminogen kinase derivative (rPA); plasminogen activator inhibitor (PAI-1). NIHSS and Simple Mental State Scale MMSE scores at different periods before and after treatment. Results: There was no significant difference between the two groups, and there was no association with occlusion. Type 2 diabetes mellitus, blood glucose, systolic blood pressure, NIHSS score, onset-thrombolysis time were statistically significant. The rPA and PAI-1 values were 25.23 ± 1.57 and 48.56 ± 5.23; the values of rPA and PAI-1 decreased continuously after treatment. The NIHSS and MMSE scores were 15.23 ± 2.61 and 12.45 ± 1.85; the NIHSS scores and MMSE scores increased continuously (P <0.05). Conclusion: Type 2 diabetes mellitus, blood glucose, systolic blood pressure, NIHSS score, and onset-thrombolysis time were considered. Re-occlusion and treatment with tirofiban can improve the neurological function and improve the therapeutic effect.

alteplase intravenous thrombolysis; cerebral infarction; reocclusion; tirofiban